CAR NK CELL THERAPY:
ADVANCED OPTIONS & GLOBAL ACCESS

To grasp the reason behind the significant leap of CAR NK cell therapy over CAR-T cell therapy, it is first necessary to understand the nature of natural killer cells and their fundamental distinction from the T-cells that are used in CAR-T cell therapy. The distinction between the two types of cells is clinically significant in terms of safety, ease of access, and the types of cancer targeted.

“The NK anti-tumor paradox: NK cells are most active against tumor cells that have lost expression of HLA class I antigens, which are the tumor cells that have evaded T-cell recognition. This is a complementary anti-tumor activity that allows CAR NK therapy to also target cancer cells that have evaded CAR-T therapy. In terms of antigen escape and loss of HLA expression, these are the two most common resistance patterns to CAR-T therapy, and CAR NK cells provide an alternative anti-tumor activity that is not dependent on HLA expression.”

Natural killer cells are large granular lymphocytes of the innate immune system, the body's first responders against viral infections and tumor cells. Their ability to kill cancer cells without prior antigen sensitization is the fundamental advantage that makes them ideal for allogeneic (off-the-shelf) cellular therapy.

“NK cells recognize "missing self," cancer cells that have lost HLA class I expression to evade T-cell recognition. This makes NK cells and T cells complementary cancer killers, not competitors.”

• Missing Self Recognition: The Key Principle

  Normal cells express MHC class I (HLA), which activates inhibitory receptors (KIR, NKG2A) on NK cells — preventing killing. Cancer cells that lose HLA expression to evade T cells remove this inhibitory signal — triggering NK cell activation. This is "missing self" surveillance, the basis of NK cell anti-tumour activity.

• How NK Cells Kill Cancer: Three Mechanisms

  NK cells form an immunological synapse and release cytotoxic granules (perforin + granzymes) causing target cell apoptosis. They express death receptor ligands (TRAIL, FasL) triggering target cell death. They also kill antibody-coated cancer cells via ADCC through the CD16 (FcγRIII) receptor — synergising with therapeutic monoclonal antibodies.

• The Alloreactivity Advantage: Why NK Cells Don't Cause GvHD

  T cells recognise HLA molecules as "self" or "foreign" using the TCR — causing GvHD when donor T cells attack recipient tissues. NK cells have no TCR and therefore no HLA-restricted alloreactivity. Allogeneic NK cells from any donor can be safely infused into HLA-mismatched patients without causing GvHD — the foundational principle enabling off-the-shelf CAR NK manufacture.

• NK Cell Distribution and Abundance

  NK cells constitute 5–20% of circulating lymphocytes and are found in blood, lymphoid organs, liver, lungs, and uterus. This broad distribution and relative abundance makes them a practical starting material for large-scale manufacturing — either from peripheral blood leukapheresis, umbilical cord blood banks, or iPSC differentiation.

CAR NK does not replace CAR-T in indications where CAR-T has proven curative activity (DLBCL: 40–54% CR; ALL: 70–90% CR in paediatric). Rather, CAR NK addresses the global access crisis — bringing cellular immunotherapy to the 90%+ of patients who cannot access approved CAR-T.

The NK cell source profoundly affects manufacturing feasibility, product consistency, in vivo persistence, and clinical outcomes. Each platform has distinct advantages guiding its selection for specific clinical programmes.

The CAR NK evidence base is predominantly Phase I and II. The MD Anderson 2020 landmark trial established clinical proof of concept. China's expanding programme has confirmed the safety signal and extended efficacy data to additional antigens and cancer types.

• MD Anderson Landmark Trial (2020) — The Pivotal Dataset

  Liu et al., Nature Medicine 2020: 11 patients with relapsed/refractory CD19+ B-cell malignancies or CLL treated with cord blood-derived IL-15-armed CD19-CAR NK cells. Results: 73% ORR (8/11 patients), 7 complete responses. Zero grade 3+ CRS, zero ICANS, zero GvHD. This trial proved the concept — comparable efficacy to CAR-T with fundamentally superior safety — and catalysed the global CAR NK trial expansion.

• Nanjing Drum Tower Hospital — CD19 CAR NK (Peripheral Blood)

  Phase I/II: >20 patients with relapsed/refractory DLBCL and ALL. Response rates 50–65% in DLBCL. Minimal grade 3–4 toxicity. Confirms safety and preliminary efficacy of peripheral blood-derived CAR NK in the Chinese setting. This is the largest single-centre Chinese CD19-CAR NK dataset.

• Soochow University — NKG2D-CAR NK in AML

  Phase I: NKG2D-based CAR NK cells targeting NKG2D ligands on AML blasts. Peripheral blood and bone marrow blast reduction in the majority of treated patients. Unique pan-tumour applicability of NKG2D as antigen recognition domain (recognises stress-induced ligands upregulated across multiple cancer types). Minimal severe toxicity.

• Zhejiang University — HER2-CAR NK in Solid Tumours

  Phase I: HER2-directed peripheral blood CAR NK in HER2+ advanced solid tumours (breast, gastric, lung cancer). Disease control rate ~60%. First Chinese solid tumour CAR NK dataset. Confirms that CAR NK extends beyond haematological malignancy with manageable toxicity in solid tumour patients.

Antigen confirmation is a prerequisite for CAR NK trial eligibility. CancerFax identifies whether the patient's tumour has been tested for the relevant antigen and coordinates testing if not completed.

The safety advantage of CAR NK over CAR-T is the most clinically significant differentiator — enabling treatment of older patients, those with comorbidities, and patients in centres without intensive care neurology units. Understanding the mechanisms behind this difference is essential for informed decision-making.

1. 1

   CRS: Rare and Mild (Grade 1–2 Only in Published Trials)

   CAR-T CRS is driven by massive cytokine production from exponentially expanding T cells and their activation of macrophages. NK cells expand far less than T cells and are gradually cleared within weeks — limiting both the volume and duration of cytokine production. Grade 3+ CRS has not been reported in any major CAR NK published series. Grade 1–2 CRS (fever, chills) occurs in 10–30% and is managed with antipyretics.

2. 2

   ICANS: Zero Confirmed Cases in Published CAR NK Series

   ICANS (confusion, aphasia, encephalopathy) in CAR-T therapy results from CNS endothelial damage from high circulating IL-1, IL-6, and other cytokines produced by massively expanded T cells. NK cells do not expand to the same degree and do not traffic to the CNS in the same way. ICANS has not been observed in any published CAR NK series — enabling treatment at centres without neurological ICU capability.

3. 3

   GvHD: <5% (Mild) in All Published Allogeneic CAR NK Series

   As NK cells lack TCR-mediated HLA recognition, they do not cause the classic T-cell-mediated GvHD syndrome. GvHD events in published allogeneic CAR NK series are rare (<5%) and universally mild (Grade 1–2), resolving without major intervention. This enables off-the-shelf manufacture from any healthy HLA-mismatched donor.

4. 4

   Cytopenia: Expected from Conditioning (Not from the CAR NK Product)

   Blood count suppression during CAR NK trials occurs from the lymphodepleting conditioning chemotherapy (fludarabine + cyclophosphamide) administered before infusion — not from the CAR NK cells themselves. This is predictable and managed with standard transfusion support and growth factors as per conditioning protocol.

5. 5

   Macrophage Activation Syndrome (MAS): Rare but Monitor

   MAS — a rare hyperinflammatory syndrome distinct from CRS — has been reported in isolated CAR NK cases. It is more intense than grade 1–2 CRS and requires corticosteroids and targeted anti-inflammatory drugs. Patients should be monitored for persistent high fever, hyperferritinaemia, and cytopenias beyond the expected conditioning period.

CAR NK cell therapy is investigational — available through clinical trials only. The following indications represent the highest-priority trial access pathways based on existing biological rationale and available clinical data.

• R/R B-Cell Malignancies Post CAR-T (DLBCL, ALL, CLL)

  Patients who relapsed after CD19 CAR-T — either through antigen escape (CD19-negative relapse) or loss of CAR-T persistence — are the strongest CAR NK indication. Bispecific CD19+CD22 CAR NK constructs can re-target escaped disease. This is the most compelling access pathway for the growing population of CAR-T failures.

• Relapsed/Refractory AML

  AML has no approved CAR-T product. NK cells have natural anti-AML activity (AML blasts frequently lose HLA and upregulate NKG2D ligands). CD33, CD123, and NKG2D-based CAR NK constructs are in Phase I with promising blast reduction data. For older AML patients where allogeneic SCT is not feasible, CAR NK trial access is the most promising cellular therapy pathway.

• Advanced HCC Refractory to Systemic Therapy

  GPC3-directed and NKG2D-based CAR NK programmes at PersonGen and Zhejiang University are specifically designed for HCC — leveraging NK cells' natural hepatic immune surveillance. For patients with advanced HCC refractory to sorafenib, lenvatinib, or atezolizumab-bevacizumab, GPC3-directed CAR NK trial access in China is the most advanced investigational cellular therapy option.

• HER2+ Solid Tumours (Breast, Gastric, Lung)

  For patients with HER2-positive advanced solid tumours who have received trastuzumab-based therapy and progressed, HER2-directed CAR NK Phase I trials at Zhejiang University represent the only available cellular immunotherapy option. Disease control rates of ~60% in Phase I. ADCC synergy with ongoing trastuzumab is a specific biological advantage.

China runs over 60% of globally registered CAR NK trials. CancerFax has direct relationships with principal investigators at the major trial sites and manages the end-to-end access process for international patients.

1. 1

   Eligibility Pre-Assessment (3–5 Business Days)

   Upload medical records to CancerFax. Our clinical team reviews diagnosis, prior treatment history, organ function, ECOG status, and molecular profile against the eligibility criteria of currently enrolling Chinese CAR NK trials. Antigen testing (CD19, CD33, HER2, GPC3, NKG2DL) is confirmed or coordinated through partner laboratories.

2. 2

   Principal Investigator Contact and Trial Submission

   CancerFax submits the case summary and translated records to the PI at the appropriate trial site (Tongji Hospital, Zhejiang University, Nanjing Drum Tower, Soochow University, PersonGen/ImmVira). PI review and screening confirmation typically takes 1–3 weeks.

3. 3

   Trial Logistics Planning and Admission

   For confirmed-eligible patients: CancerFax coordinates medical visa documentation, hospital admission scheduling, pre-trial evaluation appointments (organ function panel, ECOG assessment, infectious disease screening), accommodation near the trial site, and interpreter services.

4. 4

   Conditioning and CAR NK Infusion

   Lymphodepleting conditioning (fludarabine + cyclophosphamide, typically 3 days) clears space for CAR NK cells. CAR NK infusion follows 24–48 hours after conditioning completion. For off-the-shelf products, the product is thawed and infused the same day — no manufacturing wait.

5. 5

   Post-Infusion Monitoring (4–6 Weeks at Trial Site)

   Patients require 4–6 weeks of monitoring at the trial site — daily observations for CRS, GvHD, and infection in the first 2 weeks, then twice-weekly assessments until safe for return home. CancerFax coordinates the monitoring schedule and communicates findings to the home oncologist.

6. 6

   Remote Follow-Up After Return Home

   After discharge: monthly telemedicine follow-up between the trial team and home oncologist. Response assessment (CT/PET-CT, bone marrow biopsy where applicable) at 3 months. CancerFax provides ongoing coordination for the duration of follow-up — bridging the trial team in China with the patient's local haematologist.

Data from published trials and clinical series defining the current state of CAR NK cell therapy evidence.

• 73%ORR — MD Anderson Landmark TrialObjective response rate in relapsed B-cell malignancies with cord blood CD19-CAR NK. Zero grade 3+ CRS, ICANS, or GvHD in any of the 11 patients.
• 60%+Global CAR NK Trials in ChinaChina runs over 60% of all globally registered CAR NK clinical trials — the most active national programme by far.
• <5%GvHD Rate Across All Allogeneic CAR NK SeriesUniformly mild (Grade 1–2) in all published series — confirming the fundamental safety advantage of NK cell allotherapy.
• 0Grade 3+ ICANS Cases in All Published CAR NK TrialsZero confirmed grade 3+ ICANS in any published CAR NK series — enabling treatment at centres without neurological ICU capability.

China's dominance in global CAR NK development reflects its enormous patient burden, GMP manufacturing infrastructure built through the CAR-T programme, and national biotechnology investment in next-generation cell therapy.

For patients who can access approved CAR-T, the decision between approved CAR-T and investigational CAR NK trial access involves specific clinical considerations. The following table provides a structured framework.

Frequently Asked Questions